Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease

Neurobiology of Aging

Volumn 27, Issue 8, 2006, Pages 1110-1117

  Garcia Alloza, Monica ^a   Tsang, Shirley W ^b   Gil Bea, Francisco J ^a   Francis, Paul T ^c   Lai, Mitchell K ^b,c   Marcos, Beatriz ^a   Chen, Christopher P ^b   Ramirez, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Behavioral and psychological syndromes of dementia (BPSD); Benzodiazepine receptors; Choline acetyltransferase (ChAT); Cognitive deficit; Cortex; GABA; GABAA receptors; GABAB receptors; Glutamate

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR; GLUTAMIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; COGNITIVE DEFECT; CONTROLLED STUDY; DENSITY; DEPRESSION; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; GABAERGIC SYSTEM; HUMAN; HUMAN TISSUE; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; COGNITION DISORDERS; DEPRESSION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; RECEPTORS, GABA; TISSUE DISTRIBUTION;

EID: 33744916788     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.06.003     Document Type: Article

References (57)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. III-R ed. (1987), American Psychiatric Press, Washington, DC
2. Armstrong D.M., Sheffield R., Mishizen-Eberz A.J., Carter T.L., Rissman R.A., Mizukami K., et al. Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease. Cell Mol Neurobiol 23 (2003) 491-505
3. Bahn S., Augood S.J., Ryan M., Standaert D.G., Starkey M., and Emson P.C. Gene expression profiling in the post-mortem human brain--no cause for dismay. J Chem Neuroanat 22 (2001) 79-94
4. Bischoff S., Leonhard S., Reymann N., Schuler V., Shigemoto R., Kaupmann K., et al. Spatial distribution of GABA(B)R1 receptor mRNA and binding sites in the rat brain. J Comp Neurol 412 (1999) 1-16
5. Bjork J.M., Moeller F.G., Kramer G.L., Kram M., Suris A., Rush A.J., et al. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101 (2001) 131-136
6. Cheetham S.C., Crompton M.R., Katona C.L., Parker S.J., and Horton R.W. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 460 (1988) 114-123
7. Chen CPLH, Alder J.T., and Bowen D.M. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 66 (1996) 1592-1598
8. Chen CPLH, Eastwood S.L., Hope T., McDonald B., Francis P.T., and Esiri M.M. Immnunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 26 (2000) 1-10
9. Cummings J.L., and Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47 (1996) 876-883
10. Cummings J.L. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol 3 (2000) 21-29
11. Doraiswamy P.M., Bieber F., Kaiser L., Krishnan K.R., Reuning-Scherer J., and Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 48 (1997) 1511-1517
12. Dringenberg H.C. Alzheimer's disease: more than a 'cholinergic disorder'-evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115 (2000) 235-249
13. Esiri M.M. The basis for behavioural disturbances in dementia. J Neurol Neurosurg Psychiatry 61 (1996) 127-130
14. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
15. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 24 (1975) 407-409
16. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
17. Francis P.T. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 18 (2003) 15-21
18. Garcia-Alloza M., Hirst W.D., Chen C.P., Lasheras B., Francis P.T., and Ramirez M.J. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and noncognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 29 (2004) 410-416
19. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen CPLH, Francis P.T., Lasheras B., et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 (2005) 442-449
20. Hirono N., Mori E., Ishii K., Ikejiri Y., Imamura T., Shimomura T., et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 50 (1998) 380-383
21. Hope T., and Fairburn C.G. The Present Behavioural Examination (PBE): the development of an interview to measure current behavioural abnormalities. Psychol Med 22 (1992) 223-230
22. Hope T., Keene J., Gedling K., Cooper S., Fairburn C., and Jacoby R. Behaviour changes in dementia. Int J Geriatr Psychiatry 12 (1997) 1062-1078
23. IPA. Behavioral and Psychological signs and symptoms in demenia (BPSSD): implications for research and treatment. Int Psychogeriatr 8 (1996) 215-552
24. Keene J., Hope T., Fairburn C.G., Jacoby R., Gedling K., and Ware C.J. Natural history of aggressive behaviour in dementia. Int J Geriatr Psychiatry 14 (1999) 541-548
25. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7 (2002) 71-80
26. Levy M.L., Cummings J.L., and Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 45 (1999) 15-22
27. Lewis D.A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 26 (2002) 143-154
28. Lloyd G.K., Lowenthal A., Javoy-Agid F., and Constantidinis J. GABAA receptor complex function in frontal cortex membranes from control and neurological patients. Eur J Pharmacol 197 (1991) 33-39
29. Lloyd K.G., Zivkovic B., Scatton B., Morselli P.L., and Bartholini G. The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 13 (1989) 341-351
30. Louzada P.R., Lima A.C., Mendonca-Silva D.L., Noel F., De Mello F.G., and Ferreira S.T. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 18 (2004) 511-5118
31. Lowe S.L., Bowen D.M., Francis P.T., and Neary D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38 (1990) 571-577
32. Lowe S.L., Francis P.T., Procter A.W., Palmer A.M., Davison A.N., and Bowen D.M. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 111 (1988) 785-799
33. Matthews K.L., Chen C.P., Esiri M.M., Keene J., Minger S.L., and Francis P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 51 (2002) 407-416
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
35. McPherson G.A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 14 (1985) 213-228
36. Mehta A.K., and Ticku M.K. An update on GABAA receptors. Brain Res 29 (1999) 196-217
37. Minger S.L., Esiri M.M., McDonald B., Keene J., Carter J., Hope T., et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55 (2000) 1460-1467
38. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
39. Mohr E., Mendis T., Rusk I.N., and Grimes J.D. Neurotransmitter replacement therapy in Alzheimer's disease. J Psychiatry Neurosci 19 (1994) 17-23
40. Pandey G.N., Conley R.R., Pandey S.C., Goel S., Roberts R.C., Tamminga C.A., et al. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res 71 (1997) 137-149
41. Parnetti L., Amici S., Lanari A., and Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev 122 (2001) 2063-2069
42. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci 22 (1999) 273-280
43. Roettger V.R., and Goldfinger M.D. HPLC-EC determination of free primary amino acid concentration in cat cisternal cerbrospinal fluid. J Neurosci Methods 39 (1991) 263-270
44. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 9 (2003) 275-308
45. Rossor M.N., Garrett N.J., Johnson A.L., Mountjoy C.Q., Roth M., and Iversen L.L. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 105 (1982) 313-330
46. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149 (1986) 698-709
47. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56 (1999) 1043-1047
48. Seidl R., Cairns N., Singewald N., Kaehler S.T., and Lubec G. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn Schmiedebergs Arch Pharmacol 363 (2001) 139-145
49. Shiah I.S., and Yatham L.N. GABA function in mood disorders: an update and critical review. Life Sci 63 (1998) 1289-1303
50. Simpson M.D., Cross A.J., Slater P., and Deakin J.F. Loss of cortical GABA uptake sites in Alzheimer's disease. J Neural Transm 71 (1988) 219-226
51. Somogyi P., Tamas G., Lujan R., and Buhl E.H. Salient features of synaptic organisation in the cerebral cortex. Brain Res Rev 26 (1998) 13-35
52. Storga D., Vrecko K., Birkmayer J.G., and Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 203 (1996) 29-32
53. Taylor M., Bhagwagar Z., Cowen P.J., and Sharp T. GABA and mood disorders. Psychol Med 33 (2003) 387-393
54. Terry Jr. A.V., and Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306 (2003) 821-827
55. Zaborszky L., Pang K., Somogyi J., Nadasdy Z., and Kallo I. The basal forebrain corticopetal system revisited. Ann N Y Acad Sci 877 (1999) 339-367
56. Zarate Jr. C.A., Du J., Quiroz J., Gray N.A., Denicoff K.D., Singh J., et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 1003 (2003) 273-291
57. Zhong P., Gu Z., Wang X., Jiang H., Feng J., and Yan Z. Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. J Biol Chem 278 (2003) 26888-26889